Tandem Diabetes Care’s Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes
The FDA cleared Tandem Diabetes Care's Control-IQ+ technology for use in pregnancy with type 1 diabetes, marking the first and only automated insulin delivery system approved for this population in the U.S. The clearance was supported by the CIRCUIT trial, which demonstrated a 12.6% improvement in time in the pregnancy-specific glucose range compared to standard therapy.
Key figures
- Drug Name
- Control-IQ+
- Hours more per day
- 3 hours
- Glucose target range mg dl
- 63-140 mg/dL
- Time in range increase pct
- 12.6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.